CVS Policy Reversal Helps Drive Eli Lilly’s Stock Price Surge

Life Science

RVMD’s Near-100% Year-To-Date Rally Sparks Valuation Debate: Has the Stock Gotten Too Pricy?

Life Science

Strong Demand for GLP-1 Drugs Drives Eli Lilly’s Leadership with New Oral Medication and Acquisitions

Life Science

Two Beaten-Down Pharma Giants: Biotech’s Cyclical Turn Delivers Prime Dip-Buy Opportunities

Life Science

Gene Editing Could Become the Next “Golden Rush” in the Pharmaceutical Industry, What Does This Mean for CRISPR Therapeutics?

Life Science

3 Popular U.S. High-Dividend ETFs: Income, Growth and Diversification

Consumer Goods, Financial Service, Life Science, Technology

Moderna Outshines Pharma Giants Lilly, Merck and Pfizer With 43% Year-to-Date Surge

Life Science

AbbVie Faces a Challenger in Johnson & Johnson, but Investors Need Not Panic

Life Science

Growth Stocks Meta and Dexcom Are Suitable for Buying and Holding Long-Term

Life Science

Three AI Healthcare Stocks Chart Distinct Growth Trajectories

Life Science, Technology

Bristol-Myers Squibb’s Stock Looks Cheap on the Surface, but Hidden Risks Lurk Beneath

Life Science

Healthcare ETF Face-off: VHT, IXJ and XBI – Which Fits Your Portfolio?

Life Science

This Health Insurance Company Is Approaching Its Profit Inflection Point

Life Science

5 Institutional-Approved High-Dividend Pharmaceutical Stocks for Passive Income Investors

Life Science

After the Market Pullback, the Defensive Value of Two Blue-Chip Stocks Stands Out

Life Science, Technology